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INTRODUCTION
Preeclampsia, which affects 3% to 5% of pregnancies (1),
is a pregnancy-specific disorder characterized by hyperten-
sion and proteinuria. It is among the leading causes of fetal
and maternal morbidity and mortality. The etiology of the
condition is unknown, but placental disorders are probably
involved in the pathophysiologic mechanism (2). Therefore,
a reliable and early placental marker could be extremely ben-
eficial in detecting pregnant women at high-risk for pre-
eclampsia.
Recently, inhibin A, a glycoprotein mainly produced by
the syncytiotrophoblast of the human placenta during preg-
nancy has been evaluated both for the prediction of preeclamp-
sia (3-5) as well as assessment of severity (6-8). Sebire et al.
(9) reported previously that inhibin A levels might increase
as early as 10 to 14 weeks of gestation, based on the obser-
vation of 7 patients who subsequently had preeclampsia. It
has been shown that maternal serum levels of inhibin A are
10-fold higher in women with severe preeclampsia compared
to gestational age matched controls (8). Fraser et al. (10) also
reported that inhibin A levels are markedly elevated in women
at the time they experience preeclampsia. In women who
subsequently developed preeclampsia, inhibin A levels were
found to be elevated at 13-18 weeks in a retrospective anal-
ysis of a Down’s screening programme (5).
Previous study has demonstrated that inhibin A levels in
maternal serum and amniotic fluid are relatively different in
normal pregnant women (11). Other studies have reported
amniotic fluid levels of inhibin A in chromosomally normal
and Down’s syndrome pregnancies (12, 13). However, mater-
nal blood and amniotic fluid obtained at the time of second
trimester genetic amniocentesis are rarely used to assess the
risk of preeclampsia. The aim of this study was to investigate
the inhibin A level in maternal serum and amniotic fluid at
the time of second trimester genetic amniocentesis in patients
who subsequently develop severe preeclampsia. In addition,
we compared the correlation between maternal serum and
amniotic fluid inhibin A levels in both normal pregnant
women and subsequently severe preeclampsia.
MATERIALS AND METHODS
Study design
A case-control study was desgined with stored maternal
serum and amniotic fluid obtained from women who under-
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Maternal Serum and Amniotic Fluid Inhibin A Levels in Women who
Subsequently Develop Severe Preeclampsia
The purpose of this study was to evaluate whether maternal serum (MS) and amni-
otic fluid (AF) inhibin A levels are elevated in patients who subsequently develop
severe preecalmpsia, and to investigate the correlation between MS and AF inhibin
A levels in the second trimester. The study included 40 patients who subsequently
developed severe preecalmpsia and 80 normal pregnant women. Inhibin A levels
in MS and AF were measured with enzyme-linked immunosorbent assay (ELISA).
The MS and AF inhibin A levels in patients who developed severe preeclampsia
were significantly higher than those in the control group (both for p<0.001). There
was a positive correlation between MS and AF inhibin A levels in patients who devel-
oped severe preeclampsia (r=0.397, p=0.011), but not in the control group (r=0.185,
p=0.126). The best cutoff values of MS and AF inhibin A levels for the prediction
of severe preeclampsia were 427 pg/mL and 599 pg/mL, respectively; the estimat-
ed ORs that were associated with these cut-off values were 9.95 (95% CI 3.8-25.9,
p<0.001) and 6.0 (95% CI 2.3-15.8, p<0.001). An elevated level of inhibin A in MS
and AF at the time of second trimester amniocentesis may be a risk factor for the
subsequent development of severe preeclampsia.
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went second trimester genetic amniocentesis between Octer-
ber 2001 and December 2003 at Samsung Cheil Hospital in
Seoul, Korea. The study groups consisted of pregnant women
who subsequently developed severe preeclampsia and nor-
motentive women who had a normal pregnancy outcome
(term gestation with a neonate with adequate weight for
gestational age).
Forty patients who developed severe preeclampsia were
matched for maternal age and gestational age at sampling
with 80 normotentive women who had a normal pregnancy
outcome. Preeclampsia was defined as hypertension (systolic
blood pressure ≥140 mmHg and diastolic blood pressure
≥90 mmHg after 20 weeks’ gestation) and proteinuria (≥
300 mg in a 24 hr urine collection or one dipstick measure-
ment of ≥1+) according to the Committee of Terminology
of American College of Obstetricians and Gynecologists
(ACOG) definition (14). Severe preeclampsia was diagnosed
on the basis of diastolic blood pressure ≥110 mmHg or sig-
nificant proteinuria (dipstick measurement of ≥2+) or the
presence of severity evidences such as headache, visual distur-
bances, upper abdominal pain, oliguria, convulsion, elevated
serum creatinine, thrombocytopenia, marked liver enzyme
elevation, and pulmonary edema. Cases with an abnormal
fetal karyotype, chromosomal abnormalities, chronic hyper-
tension, diabetes, or renal disease at the time of amniocente-
sis were excluded. The control group consisted of patients
who had a second trimester amniocentesis who delivered a
normal neonate at term without significant medical or obstet-
ric complications. The Ethics Committee of Samsung Cheil
Hospital approved the collection of these samples and the
clinical information and samples for research puroposes.
Measurement of inhibin A
Amniotic fluid was obtained by transabdominal amnio-
centesis and an aliquot of amniotic fluid was centrifuged
and stored at -70℃ until assay. Maternal blood was drawn
at the time of second trimester genetic amniocentesis, col-
lected into plain serum-gel tubes (Becton Dickinson, U.S.A.),
centrifuged, and stored at -70℃. Inhibin A levels in amniotic
fluid and maternal serum were measured with a commercially
available enzyme-linked immunosorbent assay (ELISA, Diag-
nostic Systems Laboratories, Inc., Texas, U.S.A.) according
to the manufacturer’s instructions. All samples were run in
duplicate. The inter- and intra-assay coefficients of variation
were less than 10%. 
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences version 10.0 (SPSS Inc., Chicago,
U.S.A.). Kolmogorov-Smirnov tests were used to test for
normal distribution of the data. As inhibin A levels in this
study were not normally distributed, a Mann-Whitney U
tests were used for comparison of continuous variables, and
proportions were compared with the  2 and Fisher’s exact
tests. Spearman’s rank correlation was used to assess the rela-
tionship between two variables. We used the receiver opera-
tor characteristic (ROC) analysis to determine the best cut-
off value of inhibin A level for predicting severe preeclamp-
sia and calculated the odds ratio (OR) and 95% confidence
interval (CI). A p value <0.05 was considered statistical sig-
nificance.
RESULTS
The clinical characteristics of the study population are shown
in Table 1. There were statistical differences in nulliparity,
gestational age at delivery, and birth weight between patients
who developed severe preeclampsia and those in the control
group. As expected, the blood pressures of patients who
developed severe preeclampsia were significantly higher than
those in the control group. In contrast, the groups were simi-
lar in terms of maternal age, indication for amniocentesis,
gestational age at amniocentesis and blood sampling, and
platelet count.
Fig. 1 displays inhibin A levels in the second trimester
maternal serum and amniotic fluid. The median maternal
Characteristics
Severe 
preeclampsia
(n=40)
Normal 
pregnancy
(n=80)
p
value
- Maternal age (yr) 34 (26-40) 35 (22-46) 0.294
Nulliparity* 29 (73) 41 (52) 0.031
Indication for amniocentesis
Maternal age (≥35 yr) 24 (60) 50 (62.5) 0.791
Risk of Down syndrome  7 (17.5) 14 (17.5) 1.000
by serum marker
�
Elevated maternal serum alpha 4 (10) 5 (6) 0.479
fetoprotein (MSAFP)
Abnormal ultrasound finding 2 (5) 7 (9) 0.716
Others 3 (7.5) 4 (5) 0.685
Gestational age at sampling (wk) 17.2  16.4  0.116
(14.3-22.5) (15-23)
Gestational age at delivery (wk)* 37  39  <0.001
(26.6-41.3) (35.4-41.1)
Systolic blood pressure (mmHg)* 160  120  <0.001
(110-193) (110-138)
Diastolic blood pressure (mmHg)* 100  80  <0.001
(70-120) (63-100)
Birth weight (g)* 2,640  3,370  <0.001
(744-3,690) (2,220-4,555)
Urine protein (+dipstick) 3 (2-4) - -
Platelet count (×10
3) ( /L) 225 230  0.485
(64-366) (110-376)
Table 1. Clinical characteristics of the study population 
Value expressed as median (range) or number (%).
*Statistically significant, p<0.05; 
� Elevated risk of fetal Down syndrome
by maternal serum screening test (MSAFP or triple test).454 S.-Y. Kim, H.-M. Ryu, J.-H. Yang, et al.
serum and amniotic fluid levels of inhibin A were significantly
higher in patients who developed severe preeclampsia than
those in the control group (maternal serum: median 414 pg/
mL, range 168-1,039 pg/mL vs. median 280 pg/mL, range
106-522 pg/mL, p<0.001; amniotic fluid: median 525 pg/
mL, range 142-1,305 pg/mL vs. median 275 pg/mL, range
103-882 pg/mL, p<0.001). In patients who developed severe
preeclampsia, there was a positive correlation between maternal
serum and amniotic fluid inhibin A levels (r=0.394, p=0.011)
(Fig. 2). In contrast, there was no correlation between amni-
otic fluid and maternal serum inhibin A levels in the control
group (r=0.185, p=0.126). ROC curves were constructed to
select cut-off values at which to dichotomize the level of mater-
nal serum inhibin A or amniotic fluid inhibin A to identify
the subsequent development of severe preeclampsia. The best
cut-off values of each maternal serum and amniotic fluid inhibin
A level for the prediction of severe preeclampsia were 427
pg/mL and 599 pg/mL; the estimated ORs that were asso-
ciated with these cut-off values were 9.95 (95% CI 3.8-25.9,
p<0.001) and 6.0 (95% CI 2.3-15.8, p<0.001). 
DISCUSSION
We confirmed that the median second trimester maternal
serum inhibin A levels in patients who subsequently devel-
oped severe preeclampsia was significantly higher than those
in normal pregnant women. Our data are consistent with
those of previous studies that reported an increase in serum
inhibin A concentration before the onset of preeclampsia.
Cuckle et al. (15) reported an increase in maternal serum
inhibin A concentration at 13 to 18 weeks of gestation in
28 patients who subsequently had preeclampsia. Aquilina
et al. (16) evaluated the screening efficacy of serum inhibin
A determination combined with uterine artery Doppler studies
at 15 to 19 weeks of gestation in 37 women who subsequently
had preeclampsia. King et al. (17) reported that preeclamp-
tic women had second trimester serum inhibin A levels 1.3-
fold higher than the control mean. In contrast to these reports,
some studies found no difference in second trimester serum
inhibin A levels between healthy pregnant women and women
who later developed preeclampsia (18, 19).
In preeclampsia, there is partial or complete failure of tro-
phoblastic invasion of the myometrial segments of the spiral
arteries (2), a process that normally has taken place by 20
weeks of gestation (20). The failure of trophoblastic invasion
is associated with ischaemic damage to the syncytiotrophoblast
causing functional alteration of the surface layer of the syncy-
tiotrophoblast (21). This alteration in the surface layer of the
syncytiotrophoblast has been postulated as a contributory fac-
tor for the increased ‘leakage’ of inhibin A into the maternal
circulation (22), which might explain the increase in concen-
tration of maternal serum inhibin A in preeclampsia. 
This is the first report for inhibin A levels in the second
trimester amniotic fluid of the patients who subsequently
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Fig. 1. Levels of maternal serum (A) and amniotic fluid inhibin A (B) in normal pregnancy (NP) and patients with severe preeclampsia (SPE).
*Statistically significant, p<0.05. 
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Fig. 2. Correlation between maternal serum and amniotic fluind
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developed severe preeclampsia. Our results also indicated
the amniotic fluid inhibin A levels were significantly higher
in patients who subsequently developed severe preeclampsia
than those in normal pregnant women. Moreover, inhibin
A levels in amniotic fluid were significantly higher than
those in maternal serum for this disease. We speculate that
increased inhibin A levels in amniotic fluid may enter mater-
nal circulation, leading to higher detectable levels in mater-
nal blood of patients who subsequently developed severe
preeclampsia. Further investigations for the mechanism of
inhibin A through the amniotic fluid to maternal blood are
necessary. Our data suggest that amniotic fluid may be anoth-
er significant source of inhibin A for the prediction of severe
preeclampsia.
During pregnancy, the placenta produces and secretes in-
hibin A, which then enters both the maternal and the fetal
circulation (11, 12, 23). The placental inhibin A that enters
maternal and the fetal circulation may cause an elevation in
maternal serum and amniotic fluid inhibin A levels. We
observed that the amniotic fluid inhibin A levels were posi-
tively correlated with the maternal serum inhibin A levels
in the patients who subsequently developed severe preeclamp-
sia. This correlation may be associated with increased amniotic
membrane permeability in patient with severe preeclampsia.
In conclusion, the second trimester maternal serum and
amniotic fluid inhibin A levels in pregnant women who
subsequently developed severe preeclampsia were significantly
higher than those in normal pregnant women. There is a
positive correlation between elevated maternal serum and
amniotic fluid inhibin A levels in patients who subsequently
developed severe preeclampsia. At the time of genetic amnio-
centesis, we suggest that the elevated level of inhibin A in
maternal serum and amniotic fluid may be a risk factor for
the subsequent development of severe preeclampsia, although
larger studies are needed to confirm this point.
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